Related Experiment Videos
Immortalization of human lymphocytes from a tumor-involved lymph node
Cancer Research
|October 1, 1987
Summary
Researchers developed human hybridomas from vulvar cancer patient lymphocytes to create monoclonal antibodies. These antibodies show broad reactivity against carcinoma cells, indicating potential for new cancer diagnostics and therapeutics.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Regional lymph nodes in cancer patients are potential sources of immunoreactive B-cells.
- Human-human hybridoma technology enables the production of specific monoclonal antibodies.
Purpose of the Study:
- To generate and characterize human monoclonal antibodies targeting vulvar carcinoma.
- To investigate the reactivity of these antibodies against various human cell lines.
Main Methods:
- Fusion of patient lymphocytes with human UC 729-6 hybridoma cells.
- Culture and characterization of generated human-human hybridomas.
- Assay of hybridoma supernatant reactivity against carcinoma and hematopoietic cell lines.
Main Results:
- Generated stable, tetraploid human-human hybridomas secreting immunoglobulin G (IgG).
- Six hybridomas produced IgG antibodies with broad reactivity against human carcinoma cells, including the A431 vulvar epidermoid carcinoma cell line.
- No reactivity was observed against normal hematopoietic cells, red blood cells, or fibroblasts.
- One antibody (VLN3G2) identified a 48,000 molecular weight protein from A431 cell extracts.
- Enhanced cloning efficiency of human hybrids by a T-cell parentage hybridoma supernatant suggests growth factor presence.
Conclusions:
- Regional lymph nodes of cancer patients harbor B-cells producing immunoglobulins that recognize tumor-associated antigens.
- Human monoclonal antibodies derived from these B-cells demonstrate specific reactivity towards carcinoma cells.
- This approach holds promise for developing novel diagnostic and therapeutic strategies for cancer.